Are you a Health Professional? Jump over to the doctors only platform. Click Here

Intermittent and Daily Dosing for Episodic (Periodic) Asthma

Print Friendly, PDF & Email

This is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection).

Official Title

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 1 to 5 Years



Study Type


Study Design

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further Details

Primary Outcome Measures:

  • Number of asthma episodes culminating in asthma attack over the 1-year treatment period [Time Frame: 1-year treatment period]

Secondary Outcome Measures:

  • Respiratory symptoms, safety and tolerability over the 1-year treatment period [Time Frame: 1-year treatment period]

Study Start

August 2006

Eligibility & Criteria

  • Ages Eligible for Study: 1 Year – 5 Years
  • Genders Eligible for Study: Both

Inclusion Criteria:

  • Patients aged 1 to 5 years with episodic (periodic) asthma

Exclusion Criteria:

  • Patients who are not in otherwise good health
  • Patients who have persistent asthma (continual asthma symptoms)

Total Enrolment


Contact Details

Merck Sharp & Dohme (Australia) Inc., South Granville, NSW 2142, Australia; Recruiting

  • David Woolner 61-2-9795-9500
Print Friendly, PDF & Email


Posted On: 1 January, 2013
Modified On: 16 September, 2014


Created by: myVMC